已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators

来曲唑 医学 依维莫司 乳腺癌 肿瘤科 内科学 选择性雌激素受体调节剂 临床终点 随机对照试验 癌症 妇科 三苯氧胺
作者
Ying Fan,Tao Sun,Zhimin Shao,Qingyuan Zhang,Quchang Ouyang,Zhongsheng Tong,Shusen Wang,Yang Luo,Yuee Teng,Xiaojia Wang,Shu Wang,Qiang Liu,Jifeng Feng,Kunwei Shen,Yanqiu Song,Jiayu Wang,Fei Ma,Qing Li,Pin Zhang,Binghe Xu
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (10): e213428-e213428 被引量:37
标识
DOI:10.1001/jamaoncol.2021.3428
摘要

IMPORTANCE: The effectiveness of the mammalian target of rapamycin (mTOR) inhibitor everolimus in premenopausal women with hormone receptor (HR)-positive/ERBB2-negative advanced breast cancer who experienced disease progression while receiving selective estrogen receptor modulators (SERMs) is unknown. OBJECTIVE: To compare the effectiveness of everolimus plus letrozole vs letrozole alone in premenopausal women with HR-positive/ERBB2-negative advanced breast cancer who experienced disease progression while receiving SERMs. DESIGN, SETTING, AND PARTICIPANTS: The Everolimus Trial for Advanced Premenopausal Breast Cancer (MIRACLE) was a multicenter, open-label phase 2 randomized clinical trial of everolimus plus letrozole vs letrozole alone as first-line treatment conducted from December 8, 2014, to September 26, 2018. Participants included premenopausal women with HR-positive, ERBB2-negative advanced breast cancer who experienced disease progression while receiving SERMs. Analysis was performed on an intent-to-treat basis from January 5, 2015, to December 30, 2019. EXPOSURES: Patients were randomly assigned in a 1:1 ratio to receive everolimus (10 mg orally once daily) plus letrozole (2.5 mg orally once daily) (n = 101) or letrozole alone (2.5 mg orally once daily) (n = 98). Both groups received goserelin, 3.6 mg, subcutaneously on day 1 of each 28-day cycle. Patients in the letrozole group were permitted to cross over to receive everolimus with letrozole if disease progression occurred. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS), defined as the time from randomization to confirmed disease progression or death due to any cause. RESULTS: A total of 199 women (mean [SD] age, 44.3 [6.3] years) were randomized. Patients receiving everolimus plus letrozole achieved a significantly longer median PFS compared with those receiving letrozole alone (19.4 months [95% CI, 16.3-22.0 months] vs 12.9 months [95% CI, 7.6-15.7 months]; hazard ratio, 0.64 [95% CI, 0.46-0.89]; P = .008). A total of 56 of the 98 patients in the letrozole group (57.1%) were crossed over to also receive everolimus. The median PFS after crossover was 5.5 months (95% CI, 3.8-8.2 months). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, PFS was significantly longer among premenopausal patients with HR-positive/ERBB2-negative advanced breast cancer who received everolimus plus letrozole than among those who received letrozole alone. The results revealed that everolimus was effective even among patients receiving treatment with the same endocrine agent after disease progression. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02313051.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lin完成签到,获得积分10
1秒前
满怀完成签到,获得积分10
4秒前
曾经的溪流完成签到,获得积分10
5秒前
小二郎的应助被研友_Z6Qrbn采纳,获得10
6秒前
mmmm发布了新的文献求助10
9秒前
soso完成签到 ,获得积分10
10秒前
10秒前
王木木完成签到 ,获得积分10
11秒前
小李新人发布了新的文献求助10
11秒前
ket的应助被一颗柿子树采纳,获得30
11秒前
sortie完成签到,获得积分10
14秒前
曹大壮完成签到,获得积分10
17秒前
林余发布了新的文献求助10
17秒前
露稚完成签到 ,获得积分10
17秒前
lzp完成签到 ,获得积分10
20秒前
王胜楠发布了新的文献求助10
22秒前
小巧念露完成签到,获得积分10
25秒前
土书完成签到,获得积分10
25秒前
26秒前
彭于晏的应助被科研通管家采纳,获得10
27秒前
笙笙的应助被科研通管家采纳,获得10
27秒前
斯文败类的应助被科研通管家采纳,获得10
28秒前
28秒前
万能图书馆的应助被上善若水采纳,获得10
28秒前
笙笙的应助被科研通管家采纳,获得10
28秒前
汉堡包的应助被科研通管家采纳,获得10
28秒前
田様的应助被科研通管家采纳,获得10
28秒前
ffff完成签到 ,获得积分10
32秒前
兰高锋发布了新的文献求助30
32秒前
温暖无招完成签到 ,获得积分10
36秒前
17完成签到,获得积分10
36秒前
贪玩千儿完成签到,获得积分10
38秒前
liza发布了新的文献求助10
42秒前
爆米花的应助被YCLING采纳,获得10
42秒前
JamesPei的应助被wjw采纳,获得30
46秒前
nanfeng完成签到 ,获得积分10
49秒前
陶醉成协完成签到,获得积分10
49秒前
隐形曼青的应助被刻苦乐天采纳,获得10
49秒前
黎明深雪完成签到 ,获得积分10
51秒前
鲅鱼饺子完成签到 ,获得积分10
52秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184917
求助须知:如何正确求助?哪些是违规求助? 9573843
关于积分的说明 21833352
捐赠科研通 7782304
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082